Skip to content

CorMedix CRMD Other long term assets of restricted cash

Other long term assets of restricted cash at other companies

Achieve Life Sciences logo
Achieve Life SciencesACHV
$52K+33.3%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$986K-32.0%
Vor Biopharma logo
Vor BiopharmaVOR
$168K-93.0%
Liberty Broadband Corporation logo
Liberty Broadband CorporationLBRDK
$57M-57.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$11.54M+51.1%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$15.59M+703%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept crmd:OtherLongTermAssetsRestrictedCash.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's other long term assets of restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's other long term assets of restricted cash?
CorMedix (CRMD) reported other long term assets of restricted cash of $332K in Q1 2026.
What does other long term assets of restricted cash mean?
This represents cash or cash equivalents that are restricted from general use for a period exceeding one year, often due to long-term debt covenants, collateral requirements, or legal agreements. It indicates capital that is tied up and unavailable for immediate investment or operational expansion. Tracking this balance provides insight into the long-term financial encumbrances and the company's overall capital flexibility.